Celldex discontinues late-stage study of brain cancer vaccine

(Reuters) - Celldex Therapeutics Inc said it would discontinue a late-stage study of its brain cancer vaccine after an independent interim analysis suggested the therapy might not show a statistically significant benefit in survival compared with standard chemotherapy.

http://ift.tt/1StPptL

from Reuters: Health News
via animenewspro